Etanercept reduces work, activity impairment in RA

Etanercept reduces work, activity impairment in RA
For patients with moderate-to-severe rheumatoid arthritis, continued etanercept treatment is associated with reduced work and activity impairment, according to a study published online April 1 in Arthritis Care & Research.

(HealthDay)—For patients with moderate-to-severe rheumatoid arthritis (RA), continued etanercept treatment is associated with reduced work and activity impairment, according to a study published online April 1 in Arthritis Care & Research.

Devon Hone, from McKesson Specialty in Toronto, and colleagues recruited 204 RA patients (mean age, 46.6 years) initiating etanercept (50 mg/week) between January 2009 and March 2010 to quantify its impact on work and activity impairment. Telephone interviews were conducted at baseline and one, two, three, and six months after etanercept initiation to assess , activity impairment, and domestic productivity. The costs of work impairment were estimated using the human capital approach.

The researchers found that the 153 patients who remained on treatment after six months (continuers) exhibited significant decreases in overall work impairment (41.9 percent at baseline versus 25.2 percent at six months); absenteeism (8.4 versus 2.3 percent); presenteeism (38.9 versus 24.3 percent); and activity impairment (55.7 versus 30.9 percent). They also had a significant, 76.4 percent reduction in weekly work hours lost due to RA (3.2 versus 0.8 hours). For the continuers, the projected 12-month gain in work productivity was 284.5 hours per patient, equivalent to $3,233 to $22,533, depending on the annual income level. This gain partly or completely offset the annual cost of treatment ($20,190). At six months, domestic productivity was 69.9 percent, marking a significant improvement from 41.5 percent at baseline.

"In U.S. employed, moderate-to-severe RA patients, etanercept led to significant reductions in overall work and activity impairment; the value of the increased work productivity partially or completely offset the cost of treatment," the authors write.

Several authors were employees or former employees of McKesson Specialty, which was contracted by Amgen to conduct the study. The research was funded by Immunex Corporation, a subsidiary of Amgen and Wyeth.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Data suggest smoking doesn't impact RA treatment response

Dec 21, 2012

(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according ...

In veterans with RA, PTSD worsens disease activity

Feb 13, 2013

(HealthDay)—For U.S. veterans with rheumatoid arthritis (RA), a diagnosis of posttraumatic stress disorder (PTSD) is associated with worse patient-reported outcomes and tender joint counts, according to ...

Low-income patients skip rheumatoid arthritis meds

Jun 30, 2013

(HealthDay)—Electronic monitoring shows that ethnically diverse and economically disadvantaged patients with rheumatoid arthritis (RA) have low adherence to oral disease-modifying antirheumatic drugs (DMARDs) ...

Recommended for you

ACR: Most hospitalizations for gout are preventable

Nov 18, 2014

(HealthDay)—Most hospitalizations for a primary diagnosis of gout are preventable, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in ...

TNF inhibitors may increase cancer risk in the eye

Nov 17, 2014

One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called TNF inhibitors. They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.